These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease. Ann Intern Med; 2006 May; 144(9):I24. PubMed ID: 16670129 [No Abstract] [Full Text] [Related]
3. Ramipril for treatment of intermittent claudication. Poredos P Vasa; 2013 Jul; 42(4):237-8. PubMed ID: 23823855 [No Abstract] [Full Text] [Related]
4. Ramipril improves walking times and quality of life in patients with stable intermittent claudication. Brittenden J Evid Based Med; 2014 Feb; 19(1):16. PubMed ID: 23842688 [No Abstract] [Full Text] [Related]
5. ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication. Jaar BG Ann Intern Med; 2013 Jun; 158(12):JC7. PubMed ID: 23778931 [No Abstract] [Full Text] [Related]
8. Medications for improving walking performance in peripheral artery disease: still miles to go. McDermott MM JAMA; 2013 Feb; 309(5):487-8. PubMed ID: 23385276 [No Abstract] [Full Text] [Related]
9. [The reduction of cardiovascular risk with ramipril]. Vanuzzo D Ital Heart J Suppl; 2000 May; 1(5):713-4. PubMed ID: 10834142 [No Abstract] [Full Text] [Related]
10. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P; J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027 [TBL] [Abstract][Full Text] [Related]
11. ACE inhibitors and high-risk patients. Myers KA CMAJ; 2000 Aug; 163(3):327. PubMed ID: 10951738 [No Abstract] [Full Text] [Related]
12. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Salehian O; Healey J; Stambler B; Alnemer K; Almerri K; Grover J; Bata I; Mann J; Matthew J; Pogue J; Yusuf S; Dagenais G; Lonn E; Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288 [TBL] [Abstract][Full Text] [Related]
13. [The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology]. Karakin AA; Khrustalev OA; Bol'shakova MA; Forsilov VE Ter Arkh; 1996; 68(2):43-6. PubMed ID: 8771657 [No Abstract] [Full Text] [Related]
14. Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study. Hathial M Indian Heart J; 2008; 60(3):200-4. PubMed ID: 19240307 [TBL] [Abstract][Full Text] [Related]
16. Effect of ramipril on the incidence of diabetes. Potter BJ; LeLorier J N Engl J Med; 2007 Feb; 356(5):522-3; author reply 523-4. PubMed ID: 17274113 [No Abstract] [Full Text] [Related]
17. Effect of ramipril on the incidence of diabetes. Epstein BJ; Cooper-DeHoff RM N Engl J Med; 2007 Feb; 356(5):523; author reply 523-4. PubMed ID: 17269176 [No Abstract] [Full Text] [Related]
18. Impact of ramipril on the circadian periodicity of acute myocardial infarction. Dagenais GR; Pogue J; Teo KK; Lonn EM; Yusuf S; Am J Cardiol; 2006 Sep; 98(6):758-60. PubMed ID: 16950179 [TBL] [Abstract][Full Text] [Related]
19. Effect of ramipril on the incidence of diabetes. Bangalore S; Messerli FH N Engl J Med; 2007 Feb; 356(5):522; author reply 523-4. PubMed ID: 17267916 [No Abstract] [Full Text] [Related]
20. Effect of ramipril on postrevascularization prevalence of angina and quality of life. Kjøller-Hansen L; Steffensen R; Grande P Int J Cardiol; 2004 Jun; 95(2-3):159-65. PubMed ID: 15193814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]